Protocol Fast Facts

[ RTOG ]

RTOG Protocols are approved for use at Radiation Facilities:
Epic Care in Dublin
Epic Care Partners in Cancer Care – Emeryville

Approved at all NCORP Institutions


GI Protocols

1. RTOG 0848 / NCT01013649
Resected head of Pancreas Adenocarcinoma

Eligibility: Curative resection or primary invasive tumor (head of pancreas); stage T1-3, N0-1, M-0; 21-70 days interval between surgery and 1st step registration; post resection serum CA19-9 < 180 units/mL; Performance status 0-1; no prior chemo or RT for this cancer.
RX: (1st Step): (Arm 1) – Gemcitabine x 5 cycles à (if no progression, then randomize 2nd Step): (Arm 3) - 1 cycle of chemotherapy versus (Arm 4) - 1 cycle chemotherapy followed by xRT w/either capecitabine or 5-FU. (NO DRUG SUPPLIED)

GU Protocols: Prostate

1. RTOG 0924 / NCT01368588 (QOL closed eff: 3/9/15)
Unfavorable, Intermediate or Favorable High Risk Prostate Cancer

Eligibility: Pathologic dx prostatic adenocarcinoma w/in 180 days at moderate to high risk for recurrence defined as: Gleason score 7-10 +T1c-T2b (palpation) + PSA < 50 OR Gleason score 6 + T2c-T4 (palpation) + PSA < 50 OR Gleason score 6 + > 50% (positive) biopsies + PSA < 50 OR Gleason score 6 + T1c-T2b (palpation) + PSA > 20. If previously dx low risk then re-biopsied with unfavorable intermediate risk or favorable high risk are now eligible w/in 180 days from repeat bx; clinical negative nodes by imaging (no dissection); no bone mets; PS 0-1; No previous: radical surgery, pelvic irradiation, hormonal therapy, chemo for this prostate cancer.
RX: Neoadjuvant androgen deprivation therapy + prostate & seminal vesicle RT + boost to prostate & proximal seminal vesicles versus Neoadjuvant androgen deprivation therapy + whole-pelvic RT + boost to prostate & proximal seminal vesicles (NO DRUG SUPPLIED)

Head and Neck Protocols

1. RTOG 0920 / NCT01311063
SCC (and variants) of the Oral Cavity, Oropharynx or Larynx

Eligibility: Clinical stage T1, N1-2 or T2-3, N0-2, M0; gross total resection of primary with curative intent; must enroll within 7 weeks post-op; tumor must have 1 or more intermediate risk factors (see protocol p17 section; performance status 0-1;
RX: IMRT alone versus IMRT + Cetuximab (CETUXIMAB SUPPLIED) IMRT credentialling required- see protocol p. 20, section 5.3

Lung Protocols: Small Cell

1. CALGB 30610 (RTOG 0538) / NCT00632853 (QOL closed eff: 8/30/17)
Limited Stage - Small Cell Lung Cancer

Eligibility: Pathologically documented Small Cell Lung CA; No prior surgical resection; Restricted to one hemithorax; No pleural effusions; Must have measurable disease > 2 cm (or > 1 cm spiral CT); only 1 prior cycle of Cisplatin and Etoposide allowed (but all pre-study tests must be done before); no prior RT; PS = 0-2.
Cisplatin + Etoposide x 4 cycles w/RT for 3 weeks versus Cisplatin + Etoposide x 4 cycles w/RT for 7 weeks. (NO DRUGS SUPPLIED)


  • ACOSOG = American College of Surgeons Oncology Group
  • ACRIN = American College of Radiology Imaging Network
  • Alliance = Alliance for Clinical Trials in Oncology = Consolidation of ACOSOG-CALGB-NCCTG Cancer Research Groups
  • CALGB = Cancer and Leukemia Group B
  • CCCWFU = Comprehensive Cancer Center at Wake Forest University
  • COG = Children’s Oncology Group
  • CTSU = Cancer Trials Support Unit
  • ECOG = Eastern Cooperative Oncology Group
  • ECOG-ACRIN = Consolidation of ECOG-ACRIN Cancer Research Groups
  • GOG = Gynecologic Oncology Group
  • IBCSG = International Breast Cancer Study Group
  • NCI = National Cancer Institute
  • NCCTG = The North Central Cancer Treatment Group
  • NCORP = NCI Community Oncology Research Program
  • NRG Oncology = Consolidation of NSABP-RTOG-GOG Cancer Research Groups
  • NSABP = National Surgical Adjunct Breast and Bowel Project
  • PACCT = Program for the Assessment of Clinical Cancer Tests
  • RTOG = Radiation Therapy Oncology Group
  • SCUSF = SunCoast CCOP Research Base
  • SWOG = Southwest Oncology Group

REVISED 10/10/17